ScreenerHero

RNXT RenovoRx, Inc.

NAS · US · Healthcare · Biotechnology · renovorx.com
1.370USD-1.44%Mkt Cap: 61.83M $P/E: —

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is che…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap61.83M USD
Enterprise Value53.64M USD
Revenue (TTM)1.98M USD
Gross Profit796.00K USD
Net Income (TTM)-11.17M USD
Revenue/Share0.05 USD
Last Price1.370 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-11.58
PEG—
EV/EBITDA-4.12
EV/Revenue27.15
P/S31.75
P/B6.98
EPS (TTM)-0.29
EPS (Forward)-0.12
52W Range
0.701035% of range2.590
52W High2.590 USD
52W Low0.7010 USD
Profitability
Gross Margin70.88%
Oper. Margin-368.43%
EBITDA Margin0.00%
Profit Margin-994.48%
ROE-205.98%
ROA-137.96%
Growth
Revenue Growth115.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.97M USD
CapEx (TTM)2.00K USD
FCF Margin-336.44%
FCF Yield-10.75%
Net Debt-9.09M USD
Net Debt/EBITDA0.70
Balance Sheet
Debt/Equity0.04
Current Ratio5.74
Quick Ratio5.29
Book Value/Sh0.20 USD
Cash/Share0.21 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)7.125 USD
Upside (mean)+420.1%
Target Range3.000 USD – 14.50 USD
3.000+420.1% to mean14.50
# Analysts4
Ownership
Shares Out.45.13M
Float39.17M
Insiders3.60%
Institutions20.38%
Short Interest
Short Ratio0.5d
Short % Float1.54%
Short % Out.1.49%
Shares Short673.56K
Short (prev mo.)674.02K
Technical
SMA 501.497 (-8.5%)
SMA 2001.071 (+27.9%)
Beta0.97
S&P 52W Chg16.45%
Avg Vol (30d)1.08M
Avg Vol (10d)520.48K
Technical Indicators
RSI (14)39.7
MACD-0.0236
MACD Signal0.0382
MACD Hist.-0.0618
BB Upper2.195 USD
BB Middle1.696 USD
BB Lower1.197 USD
BB Width58.83%
ATR (14)0.1594 USD
Vol Ratio (20d)0.60x